Arcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Should l Buy RCUS?
Source: Newsfilter
- Clinical Trial Advancement: Arcus is executing its ongoing PEAK-1 Phase 3 trial to establish casdatifan as the standard of care for clear cell renal cell carcinoma, with a goal of rapid patient enrollment to complete the study within 18 months.
- Data Presentation Plans: At least three data presentations for casdatifan are anticipated in 2026, including updated progression-free survival (PFS) data from the ARC-20 study involving 121 patients, to be showcased at a medical conference in February 2026.
- Financial Stability: With approximately $1 billion in cash and investments, Arcus expects to fund its operations until at least the second half of 2028, ensuring the continuity of its development plans.
- New Drug Development: Arcus aims to advance its first small molecule MRGPRX2 antagonist into clinical development in 2026, targeting chronic spontaneous urticaria, highlighting the company's strategic focus in the inflammation and immunology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCUS
Wall Street analysts forecast RCUS stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 24.250
Low
14.00
Averages
27.44
High
44.00
Current: 24.250
Low
14.00
Averages
27.44
High
44.00
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcus Biosciences Halts Late-Stage Lung Cancer Trial
- Trial Termination Reason: Arcus Biosciences announced the discontinuation of the STAR-121 trial in collaboration with Gilead Sciences due to futility, indicating poor clinical prospects for the anti-TIGIT therapy domvanalimab, which may impact the company's future R&D direction.
- Clinical Trial Details: The STAR-121 trial evaluated domvanalimab combined with chemotherapy and the anti-PD-1 antibody zimberelimab as a first-line treatment for metastatic non-small cell lung cancer, but the Independent Data Monitoring Committee's recommendation led to its early termination, revealing insufficient efficacy of the therapy.
- Other Study Cessation: The company also announced the halt of the Phase 2 EDGE-Lung study, which assessed domvanalimab with various immunotherapies, further indicating significant challenges in its lung cancer research and potentially affecting its market competitiveness.
- Collaboration Rights Change: Arcus disclosed that effective July 14, 2026, Gilead will no longer hold option rights to certain early-stage pipeline projects due to the non-payment of option continuation fees, which may impact Arcus's cash flow and future collaboration opportunities.
See More
ARCUS BIOSCIENCES INC - SEC FILING ANNOUNCES DISCONTINUATION OF STAR-121 AND PHASE 2 EDGE-LUNG STUDIES
ARCUS Biosciences Updates: ARCUS Biosciences is continuing its studies on STAR-121 and Phase 2 Edge-Lung, focusing on advancements in their research and development efforts.
SEC Filing: The company has filed with the SEC, indicating ongoing regulatory compliance and transparency in its operations.
See More
Arcus Biosciences Grants Employee Stock Options
- Stock Option Grant: Arcus Biosciences has granted one new employee options to purchase 7,850 shares at an exercise price of $22.65, reflecting the company's commitment to attracting talent and its growth potential.
- Restricted Stock Units: The company also awarded the employee 3,950 restricted stock units, aimed at retaining key personnel and enhancing team stability through equity incentives.
- Incentive Plan Context: This grant is made under the company's 2020 Inducement Plan, which was approved in compliance with NYSE rules, demonstrating the company's foresight and compliance in attracting top talent.
- Strategic Development: Arcus Biosciences focuses on developing innovative drugs for cancer and autoimmune diseases, advancing its clinical trials to improve patient survival rates, showcasing its strategic positioning in the biopharmaceutical sector.
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 7,050 shares to two new employees at an exercise price of $21.41 per share, based on the closing price on March 23, 2026, reflecting the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 3,550 shares in restricted stock units, aimed at further attracting and retaining talent, thereby enhancing team stability and execution capabilities.
- Incentive Plan Context: The stock grants are made under the company's 2020 Inducement Plan, approved by the Board of Directors, complying with the NYSE Listed Company Manual Rule 303A.08's
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 17,050 shares to two new employees at an exercise price of $23.43, reflecting the closing price on March 9, 2026, indicating the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 8,550 shares in restricted stock units, further enhancing its long-term incentive mechanisms aimed at attracting and retaining key personnel to support its growth trajectory.
- Inducement Plan Context: The stock grants were made under the company's 2020 Inducement Plan, which was approved in January 2020, aligning with the
See More
Arcus (RCUS) Q4 2025 Earnings Call Transcript
See More
Arcus Biosciences Halts Late-Stage Lung Cancer Trial
- Trial Termination Reason: Arcus Biosciences announced the discontinuation of the STAR-121 trial in collaboration with Gilead Sciences due to futility, indicating poor clinical prospects for the anti-TIGIT therapy domvanalimab, which may impact the company's future R&D direction.
- Clinical Trial Details: The STAR-121 trial evaluated domvanalimab combined with chemotherapy and the anti-PD-1 antibody zimberelimab as a first-line treatment for metastatic non-small cell lung cancer, but the Independent Data Monitoring Committee's recommendation led to its early termination, revealing insufficient efficacy of the therapy.
- Other Study Cessation: The company also announced the halt of the Phase 2 EDGE-Lung study, which assessed domvanalimab with various immunotherapies, further indicating significant challenges in its lung cancer research and potentially affecting its market competitiveness.
- Collaboration Rights Change: Arcus disclosed that effective July 14, 2026, Gilead will no longer hold option rights to certain early-stage pipeline projects due to the non-payment of option continuation fees, which may impact Arcus's cash flow and future collaboration opportunities.
See More
ARCUS BIOSCIENCES INC - SEC FILING ANNOUNCES DISCONTINUATION OF STAR-121 AND PHASE 2 EDGE-LUNG STUDIES
ARCUS Biosciences Updates: ARCUS Biosciences is continuing its studies on STAR-121 and Phase 2 Edge-Lung, focusing on advancements in their research and development efforts.
SEC Filing: The company has filed with the SEC, indicating ongoing regulatory compliance and transparency in its operations.
See More
Arcus Biosciences Grants Employee Stock Options
- Stock Option Grant: Arcus Biosciences has granted one new employee options to purchase 7,850 shares at an exercise price of $22.65, reflecting the company's commitment to attracting talent and its growth potential.
- Restricted Stock Units: The company also awarded the employee 3,950 restricted stock units, aimed at retaining key personnel and enhancing team stability through equity incentives.
- Incentive Plan Context: This grant is made under the company's 2020 Inducement Plan, which was approved in compliance with NYSE rules, demonstrating the company's foresight and compliance in attracting top talent.
- Strategic Development: Arcus Biosciences focuses on developing innovative drugs for cancer and autoimmune diseases, advancing its clinical trials to improve patient survival rates, showcasing its strategic positioning in the biopharmaceutical sector.
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 7,050 shares to two new employees at an exercise price of $21.41 per share, based on the closing price on March 23, 2026, reflecting the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 3,550 shares in restricted stock units, aimed at further attracting and retaining talent, thereby enhancing team stability and execution capabilities.
- Incentive Plan Context: The stock grants are made under the company's 2020 Inducement Plan, approved by the Board of Directors, complying with the NYSE Listed Company Manual Rule 303A.08's
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 17,050 shares to two new employees at an exercise price of $23.43, reflecting the closing price on March 9, 2026, indicating the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 8,550 shares in restricted stock units, further enhancing its long-term incentive mechanisms aimed at attracting and retaining key personnel to support its growth trajectory.
- Inducement Plan Context: The stock grants were made under the company's 2020 Inducement Plan, which was approved in January 2020, aligning with the
See More
Arcus (RCUS) Q4 2025 Earnings Call Transcript
See More
